Erratum: A window-of-opportunity trial of the CXCR1/2 inhibitor reparixin in operable HER-2-negative breast cancer (Breast Cancer Research (2020) 22: 4 DOI: 10.1186/s13058-019-1243-8)

Lori J. Goldstein; Raymond P. Perez; Denise Yardley; Linda K. Han; James M. Reuben; Hui Gao; Susan McCanna; Beth Butler; Pier Adelchi Ruffini; Yi Liu; Roberto R. Rosato; Jenny C. Chang

ArticleOPEN ACCESS

Erratum: A window-of-opportunity trial of the CXCR1/2 inhibitor reparixin in operable HER-2-negative breast cancer (Breast Cancer Research (2020) 22: 4 DOI: 10.1186/s13058-019-1243-8)

Breast Cancer Research

DOI: 10.1186/s13058-020-01294-7

2Citations

8Readers

Abstract

After publication of the original article [1], the authors identified two errors in the Author details: 1. Sarah Cannon Research Institute, Nashville, TN, should be added to Dr. Yardley's affiliation in addition to Tennessee Oncology. 2. Dr. Yardley has provided services to multiple companies on behalf of Sarah Cannon Research Institute.

Cite

CITATION STYLE

APA

Goldstein, L. J., Perez, R. P., Yardley, D., Han, L. K., Reuben, J. M., Gao, H., … Chang, J. C. (2020, May 20). Erratum: A window-of-opportunity trial of the CXCR1/2 inhibitor reparixin in operable HER-2-negative breast cancer (Breast Cancer Research (2020) 22: 4 DOI: 10.1186/s13058-019-1243-8). Breast Cancer Research. BioMed Central Ltd. https://doi.org/10.1186/s13058-020-01294-7

Erratum: A window-of-opportunity trial of the CXCR1/2 inhibitor reparixin in operable HER-2-negative breast cancer (Breast Cancer Research (2020) 22: 4 DOI: 10.1186/s13058-019-1243-8)

Abstract

Cite

Register to see more suggestions